Fungal Friend, a psychoactive substance found in mushrooms, is the most common drug used by microdosers. Psilocybin is a Schedule 1 controlled substance in the United States, though possession is decriminalized or deprioritized in some states and the District of Columbia. Microdosers consume psilocybin by eating dried or fresh mushrooms, brewing them into a tea, or taking it in pill form.

While outcomes from full-dose psychedelic research can inform microdosing studies, focusing solely on known effects could miss potentially important benefits and challenges of this practice. An open, exploratory approach that begins with participants’ own reports could yield a useful data-driven taxonomy of MDBCs that could guide future intervention research by identifying high-potential constructs for study and helping researchers allocate their time and funding effectively.

Where to Buy Microdose Mushrooms Online: A Complete Guide

In addition to the a priori focal outcome of improved mood, our survey respondents reported significant improvements in other aspects of their mental health. Improved focus and creativity were among the most prominent reported benefits, and this aligns with previous research suggesting that microdosers are more creative than non-microdosers.

The third most reported benefit was reduced anxiety, which may be linked to decreased depression and a reduction in the frequency of self-harm behaviors. Improvements in these constructs align with a growing body of evidence supporting the use of psilocybin for treating depression and other mental disorders.